- Eli Lilly (NYSE:LLY +3%) net profit -12% to $727.5M
- Sales breakdown: antidepressant Cymbalta tumbles 38% to $883.2M after the treatment lost patent protection in December; chemotherapy drug Alimta +6.1%; diabetes treatment Humalog +19%.
- Patent expriations "will result in a substantial decline in revenue and earnings in 2014," CEO John Lechleiter reiterates, although the company hopes to revive sales with new products. "We anticipate launching several new medicines this year and returning our company to growth in 2015 and beyond," Lechleiter says.
- Confirms 2014 EPS of $2.77-2.85. (PR)
- Previous